



Adiponectin circulating levels and 10-year (2002–2012) cardiovascular disease incidence: the ATTICA Study

Ioannis Kyrou ^{1,2,3,4} · Olga Tsantarlioti¹ · Demosthenes B. Panagiotakos ¹ ·
Constantine Tsigos¹ · Ekavi Georgousopoulou¹ · Christina Chrysohoou⁵ ·
Ioannis Skoumas⁵ · Dimitrios Tousoulis⁵ · Christodoulos Stefanadis⁵ ·
Christos Pitsavos⁵, the ATTICA study group

Received: 27 June 2017 / Accepted: 20 September 2017 / Published online: 16 October 2017
© Springer Science+Business Media, LLC 2017

Abstract

Purpose Adiponectin is an adipokine with anti-inflammatory and cardiovascular-protective properties. Existing epidemiological evidence is conflicting on the exact relationship between adiponectin and long-term cardiovascular disease (CVD) risk. Our aim was to prospectively assess whether circulating adiponectin is associated with long-term incident CVD.

Methods A population-based, prospective study in adults (>18 years) without previous CVD history (ATTICA study). Circulating total adiponectin levels were measured at baseline (2001–2002) in a sub-sample ($n = 531$; women/men: 222/309; age: 40 ± 11 years) of the ATTICA cohort and complete 10-year follow-up data were available in 366 of these participants (women/men: 154/212; age: 40 ± 12 years).

Results After adjusting for multiple factors, including age, sex, body mass index, waist circumference, smoking, physical activity, Mediterranean diet adherence, hypertension,

diabetes, and hypercholesterolemia, our logistic regression analysis indicates that an increase in circulating total adiponectin levels by 1 unit was associated with 36% lower CVD risk (relative risk [RR]: 0.64, 95% confidence interval [CI] 0.42–0.96; $p = 0.03$). Further adjusting for interleukin-6 plasma levels had no significant impact (RR: 0.60, 95% CI 0.38–0.94; $p = 0.03$), while additional adjustment for circulating C-reactive protein (CRP) modestly attenuated this association (RR: 0.63, 95% CI 0.40–0.99; $p = 0.046$). **Conclusions** In our study, elevated circulating total adiponectin levels were associated with lower 10-year CVD risk in adults without previous CVD, independently of other established CVD risk factors. This association appeared to be modestly attenuated by CRP, yet was not mediated by interleukin-6 which is the main endocrine/circulating pro-inflammatory cytokine.

Keywords Adiponectin · Cardiovascular disease · CVD risk · ATTICA study

✉ Demosthenes B. Panagiotakos
dbpanag@hua.gr

- ¹ Department of Science of Dietetics and Nutrition, School of Health Science and Education, Harokopio University, Athens, Greece
- ² Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham B4 7ET, UK
- ³ Translational & Experimental Medicine, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
- ⁴ WISDEM, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX, UK
- ⁵ First Cardiology Clinic, School of Medicine, University of Athens, Athens, Greece

Introduction

Adipose tissue secretes in the circulation multiple proteins and factors, collectively termed as adipokines [1, 2]. Circulating adipokines exert various effects on target tissues/organs, thus regulating energy homeostasis, metabolism, insulin sensitivity, and cardiovascular functions [3, 4]. Adiponectin (initially reported as Acrp30, AdipoQ, apM1, and GBP28) is a secretory protein encoded by the ADIPOQ gene and is synthesized/secreted almost exclusively by adipocytes, constituting one of the most abundant

circulating adipokines (approximately 0.01% of the total plasma protein) [5–7].

Compiling experimental evidence has shown that adiponectin plays a pleiotropic protective role, exhibiting unique anti-inflammatory, insulin-sensitizing, anti-atherogenic and cardiovascular-protective properties [4–7]. Notably, in contrast to most other adipokines, adiponectin secretion decreases with increasing adiposity [2–7]. As such, the chronic, low-grade, systemic inflammation, which is caused by increased adiposity and is associated with cardiovascular disease (CVD), is characterized not only by increased circulating pro-inflammatory biomarkers, such as C-reactive protein (CRP) [8], and interleukin-6 (IL-6) [9], but also by lower adiponectin plasma levels [5–7].

Despite the strong experimental evidence supporting the protective cardio-metabolic role of adiponectin, the epidemiological data on the exact relationship between adiponectin and long-term CVD risk are inconsistent and conflicting [10]. Indeed, in 2004, Pischon et al. showed that high plasma adiponectin levels were associated with significantly lower myocardial infarction risk in middle-aged, CVD-free men of the Health Professionals Follow-up Study over a 6-year follow-up period [11]. However, other prospective studies have failed to identify a strong, independent association between circulating adiponectin and coronary heart disease (CHD) [12]. Moreover, data from studies in elderly participants or patients with CHD or heart failure have reported a paradoxical positive association between increasing adiponectin plasma levels and mortality [10, 13–15].

It becomes evident that long-term prospective studies are still needed in this field. Moreover, the available epidemiological data on this association from prospective cohorts in Mediterranean countries are rather limited. With the aforementioned in mind, the aim of the present work was to prospectively assess whether circulating adiponectin levels are associated with long-term CVD risk in Greek adults from the general population without previous CVD.

Materials and methods

Study sample

The ATTICA study is a population-based, prospective survey conducted in the Attica region of Greece. The detailed ATTICA study design has been previously described in the initial methodology paper [16]. Briefly, 3042 free-living adults (>18 years old; women/men: 1528/1514) without previous CVD history were recruited during 2001–2002 through a multi-stage, random sampling protocol that selected one participant per household. Comprehensive baseline assessments, including a physical examination and measurements of key biochemical parameters, were

performed in all study participants. To address the research question of the present work, in a random sub-sample of 531 study participants (women/men: 222/309; age: 40 ± 11 years) we additionally measured circulating total adiponectin levels. No significant differences were observed between the sub-sample of the present study and the total study population regarding the distributions of age, gender, physical activity status, smoking and dietary habits (all *P*-values >0.30). The ATTICA study protocol was approved by our Institutional Ethics Committee and the study was conducted according to the World Medical Association Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.

Baseline study assessments

The baseline study data included demographic characteristics (e.g., age, sex, and years of education), personal/family history of CVD, hypertension, hypercholesterolemia, and diabetes, as well as detailed information on dietary and key lifestyle habits (e.g., smoking and physical activity), as previously described [16]. Briefly, the dietary evaluation for all study participants was performed using a validated semi-quantitative food-frequency questionnaire, i.e., the EPIC-Greek questionnaire [17], which was kindly provided by the Unit of Nutrition of Athens Medical School, while adherence to the Mediterranean diet was also assessed through the MedDietScore (range 0–55; higher score values indicate better adherence) [18]. Furthermore, the International Physical Activity Questionnaire (IPAQ) was utilized, as an index of weekly energy expenditure, to assess the physical activity level of study participants (according to the IPAQ participants were classified as inactive, minimally active and healthy active) [19]. Moreover, in the context of this study, current smokers were defined as those smoking at least one cigarette per day, while ex-smokers as those who had stopped smoking for at least 1 year prior to study enrollment. Pack-years of smoking were also calculated as the product of average cigarettes smoked per day by the years of smoking.

Anthropometric parameters were measured for all participants, including height which was measured to the nearest 0.5 cm with a right-angles triangle resting of the participant's scalp and against the wall (participant without shoes and in the upright position with the back square against the measuring wall tape); weight (kilograms; kg) which was measured with a lever balance (participant in light undergarments and without shoes); and waist circumference (cm) which was measured with an inelastic measuring tape at the minimum circumference between the superior iliac crest and the lower margin of the last rib (participant in the upright position and at the end of normal expiration). For each participant, the body mass index (BMI) was also calculated

as body weight in kilograms divided by the square of the height in meters (kg/m^2). Although useful to avoid overestimating BMI in subjects older than 65 years, no particular formulas were adopted for height estimation in study participants over 65 years old. Resting arterial blood pressure (BP; mean of three recordings) in a sitting position was also measured for each participant, and participants with average BP $\geq 140/90$ mmHg [or on antihypertensive medication(s)] were classified as hypertensive. Blood samples were collected from each participant at 8–10 am, following 10–12 h of overnight fasting (no food and alcohol intake with the exception of water). Accordingly, serum and plasma samples were prepared, aliquoted and stored at -80°C until assayed. Total cholesterol, HDL-cholesterol, and triglyceride levels were measured using a chromatographic enzymatic method in a Technicon automatic analyzer RA-1000 (Dade Behring, Marburg, Germany). LDL-cholesterol was calculated using the Friedewald formula. Hypercholesterolemia was defined as total cholesterol levels >200 mg/dl (or use of lipid-lowering medications). Fasting blood glucose plasma levels were measured with a Beckman glucose analyzer (Beckman Instruments, Fullerton, CA, USA) and participants with levels >125 mg/dl [or on anti-diabetic medication(s)] were classified as having diabetes. For the purposes of this study, measurements were also performed for high sensitivity CRP plasma levels by particle-enhanced immunonephelometry [N Latex; Dade-Behring Marburg GmbH, Marburg, Germany; intra-assay and inter-assay coefficients of variation (CV): $<5\%$], as well as for total adiponectin and high sensitivity IL-6 plasma levels by enzyme-linked immunosorbent assays (R&D systems Inc, Minneapolis, Minnesota; intra-assay and inter-assay CV for both assays: $<10\%$), according to the manufacturer's protocols.

Finally, according to the results of the above baseline assessments, the study participants were also classified based on the presence or absence of metabolic syndrome at baseline according to the International Diabetes Federation (IDF) criteria/definition [20].

ATTICA study 10-year follow-up (2002–2012) and cardiovascular disease incidence

The ATTICA study 10-year follow-up was performed during 2011–2012 (median follow-up duration: 8.41 years), as previously described [21]. Data regarding the CVD health status of each study participant included development of: (a) myocardial infarction, angina pectoris, other identified forms of ischemia or coronary revascularization (i.e., coronary artery bypass surgery and percutaneous coronary intervention); (b) heart failure and chronic arrhythmias; and (c) stroke. Medical records and hospital data were obtained to confirm the CVD status of participants and the adjudication

was performed by trained study physicians following the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD10). For participants who died during the study follow-up period, the relevant information was acquired from death certificates and relatives. In the context of the present study, complete and clinically accurate data regarding the CVD status during the 10-year study follow-up were obtained for 366 participants with measured baseline total adiponectin plasma levels (Table 1). Thus, herein we present the analyzes of the adiponectin data from this working sub-sample in relation to the documented 10-year incidence of fatal/non-fatal CVD.

Statistical analysis

Continuous variables are presented as mean values \pm standard deviation (SD), and categorical variables as frequencies. Normality assumption was assessed via P–P plots. Associations between categorical variables were tested using the chi-square test, while between continuous variables using Pearson r or Spearman's ρ coefficients for normally distributed and skewed variables, respectively. Comparisons of mean values of normally distributed variables between the study participants who developed CVD and the CVD-free participants were performed using Student's t -test, after controlling for equality of variances using the Levene's test. Comparisons of continuous variables without normal distribution were performed using the non-parametric Mann-Whitney U-test. Logistic regression models were applied to estimate the relative risk of CVD during the 10-year follow up in relation to baseline circulating adiponectin levels, including adjustments for multiple confounding factors, namely age, sex, BMI, waist circumference, smoking, physical activity level, Mediterranean diet adherence, hypertension, diabetes, hypercholesterolemia, and key circulating pro-inflammatory biomarkers (i.e., IL-6 and CRP). The results of logistic regression models are presented as odds ratios (OR) and 95% confidence intervals (CI). Survival analysis using Cox Proportional Hazards models was also applied, showing similar findings (data not shown in text), but the results from logistic regression were preferred to be presented because they showed more robust statistical estimators. All reported P values are based on two-sided tests and the corresponding 95% CI. The Statistical Package for Social Sciences (SPSS) version 22 (SPSS Inc, Chicago, IL, USA) was used for all statistical analyzes.

Results

Baseline characteristics and 10-year CVD incidence

The key baseline characteristics of the study participants are summarized in Table 1. During the 10-year study follow-up,

Table 1 Selected key baseline characteristics for the total study sample ($N = 531$) and for all participants with complete 10-year follow-up and measured baseline total adiponectin plasma levels ($N = 366$) based on the development of fatal or non-fatal cardiovascular disease (CVD) during the study follow-up period

Baseline characteristics	Total study sample ($N = 531$)	Study participants with confirmed CVD status at the 10-year follow-up			<i>P</i>
		All follow-up ($N = 366$)	CVD-free ($N = 339$)	Fatal/non-fatal CVD ($N = 27$)	
Age (years)	40 ± 11	40 ± 12	39 ± 11	55 ± 9	<0.001
Gender (% male)	58	58	56	81	0.01
Education (years)	12.4 ± 3.6	12.4 ± 3.6	12.5 ± 3.5	11.3 ± 4.3	0.23
BMI (kg/m ²)	25.9 ± 4.4	26.1 ± 4.5	25.9 ± 4.5	29.1 ± 4.1	<0.001
Waist circumference (cm)	89 ± 16	90 ± 16	89 ± 15	102 ± 13	<0.001
Current smokers (% yes)	40	41	41	35	0.03
Ex-smokers (% yes)	18	17	15	43	0.02
Years stopped smoking	9.8 ± 8.1	10.1 ± 9.9	9.5 ± 8.2	12.2 ± 11.2	0.077
Pack-years of smoking	496 ± 501	501 ± 500	441 ± 426	760 ± 704	<0.001
Physical activity status (% yes) ^a	38	40	40	33	0.47
Minimally active (% yes)	25	26	26	23	
HEPA active (% yes)	13	14	14	10	
MedDietScore (range 0–55)	27 ± 6	27 ± 5	27 ± 6	23 ± 5	<0.001
Obesity (% yes)	17	18	17	33	0.04
Hypertension (% yes)	26	29	26	59	<0.001
Diabetes (% yes)	3	3	2	19	<0.001
Hypercholesterolemia (% yes)	37	40	37	78	<0.001
Metabolic syndrome (% yes) ^b	45	47	45	70	0.01
Fasting glucose (mg/dl)	89 ± 20	90 ± 19	89 ± 17	102 ± 31	0.01
Total cholesterol (mg/dl)	189 ± 37	191 ± 38	188 ± 37	220 ± 41	<0.001
Triglycerides (mg/dl)	107 ± 72	108 ± 67	104 ± 64	165 ± 78	<0.001
HDL cholesterol (mg/dl)	48 ± 14	48 ± 13	49 ± 13	40 ± 13	<0.001
LDL cholesterol (mg/dl)	120 ± 35	121 ± 35	118 ± 34	147 ± 39	<0.001
Adiponectin (µg/ml)	4.0 ± 2.0	3.9 ± 1.9	4.0 ± 1.9	2.8 ± 1.1	<0.001
IL-6 (pg/ml)	1.4 ± 0.3	1.4 ± 0.3	1.4 ± 0.4	1.6 ± 0.2	<0.001
CRP (mg/l)	1.8 ± 2.1	1.8 ± 2.2	1.7 ± 2.1	2.5 ± 2.1	0.02

Data presented as means ± standard deviation for continuous variables, and as frequencies for categorical variables. *P* values for comparisons between CVD-free participants and those with confirmed CVD at the 10-year follow-up derived using the Mann-Whitney test for continuous variables and the chi-square test for categorical variables

CVD cardiovascular disease, BMI body mass index, WC waist circumference, MedDietScore score evaluating the adherence to the Mediterranean diet (higher score values indicate better adherence), IL-6 interleukin 6, CRP C-reactive protein

^a Physical activity status: physically active participants categorized as minimally active and healthy enhancing physical active based on the IPAQ [19]

^b Metabolic syndrome defined based on the International Diabetes Federation (IDF) criteria/definition [20]

27 of the 366 (7.4%) participants with complete follow-up data and measured baseline adiponectin plasma levels had developed CVD; of these subjects 81% were men and 19% women (*P* for gender difference: 0.01; Table 1). Compared to participants who remained CVD-free, the group of participants who developed CVD during the 10-year study follow-up consisted mainly of older men, and had more pack-years of smoking and higher baseline BMI and waist circumference values (all *P* values <0.05; Table 1). This group further exhibited at baseline higher incidence of the various metabolic syndrome components (i.e., obesity,

hypercholesterolemia, hypertension and diabetes) and higher incidence of the metabolic syndrome as defined by the IDF criteria, as well as worse fasting glycemic and lipidemic profiles and lower adherence to the Mediterranean diet (i.e., lower MedDietScore) (all *P* values <0.05; Table 1).

In addition, participants who developed CVD during the study follow-up had significantly lower baseline total adiponectin plasma levels compared to those who remained CVD-free (2.8 ± 1.1 vs. 4.0 ± 1.9 µg/ml, respectively; *P* < 0.001). Finally, these participants also had an enhanced

Table 2 Correlations between circulating total adiponectin levels and selected baseline variables in the participants with complete 10-year follow-up and measured baseline adiponectin plasma levels ($N = 366$) tested by the Spearman's rank correlation coefficient

Baseline characteristics	Circulating total adiponectin levels	
	<i>r</i>	<i>P</i> value
BMI (kg/m^2)	−0.336	<0.001
Waist circumference (cm)	−0.389	<0.001
Fasting Glucose (mg/dl)	−0.161	0.002
Total cholesterol (mg/dl)	−0.088	0.096
Triglycerides (mg/dl)	−0.319	<0.001
LDL cholesterol (mg/dl)	−0.136	0.011
HDL cholesterol (mg/dl)	0.431	<0.001
MedDietScore (range 0–55)	0.343	<0.001
IL-6 (pg/ml)	−0.181	0.001
CRP (mg/l)	−0.175	0.001
Pack-years of smoking	−0.067	0.250

BMI body mass index, *WC* waist circumference, *MedDietScore* score evaluating the adherence to the Mediterranean diet (higher score values indicate better adherence), *IL-6* interleukin 6, *CRP* C-reactive protein

pro-inflammatory profile at baseline, as indicated by the significantly higher circulating levels of both IL-6 ($P < 0.001$) and CRP ($P = 0.02$), compared to participants without CVD during the 10-year study follow-up (Table 1).

Baseline associations between circulating adiponectin and key study variables

Table 2 presents the correlations between the baseline total adiponectin plasma levels and selected key baseline variables in the study participants with complete 10-year follow-up and measured baseline total adiponectin plasma levels ($N = 366$) based on Spearman's rank correlation coefficient tests. Circulating adiponectin exhibited significant negative correlations with BMI, waist circumference, triglycerides, IL-6, and CRP levels (all P values <0.001; Table 2), as well as with LDL-cholesterol and fasting glucose plasma levels ($P = 0.011$ and $P = 0.002$ respectively; Table 2). On the other hand, significant positive correlations were identified between circulating adiponectin and both the MedDietScore and HDL-cholesterol levels (both P values <0.001; Table 2).

Baseline circulating adiponectin levels and 10-year CVD incidence

The results of the multi-adjusted logistic regression models applied to assess the likelihood (odds ratio; 95% CI) for the

Table 3 Results from logistic regression analysis models estimating the relative risk (odds ratio; 95% confidence Intervals) for the development of a cardiovascular disease event (outcome) during the 10-year study follow-up period according to the baseline circulating total adiponectin levels

Model	10-year risk of a CVD event (outcome) according to the baseline circulating adiponectin levels	
	Odds ratio (95% CI)	<i>P</i> value
1	0.62 (0.42–0.91)	0.01
2	0.63 (0.43–0.92)	0.02
3	0.64 (0.42–0.96)	0.03
4	0.6 (0.38–0.94)	0.03
5	0.63 (0.4–0.99)	0.046

Model 1: adjusted for age, sex, body mass index, and waist circumference. Model 2: Model 1 additionally adjusted for current smoking (pack-years of smoking were also included to incorporate lifelong smoking habit, without any significant change in the results), physical activity and MedDietScore. Model 3: Model 2 additionally adjusted for hypertension, diabetes, and hypercholesterolemia. Model 4: Model 3 additionally adjusted for circulating Interleukin-6 levels. Model 5: Model 3 additionally adjusted for circulating C-reactive protein levels

CI confidence intervals, *CVD* cardiovascular disease, *MedDietScore* score evaluating the adherence to the Mediterranean diet (higher score values indicate better adherence)

development of CVD during the 10-year study follow-up period in relation to the baseline circulating adiponectin levels are presented in Table 3. In the context of this study, after adjusting for age, sex, BMI, and waist circumference, we found that an increase in circulating adiponectin levels by 1 unit was associated with reduced likelihood of CVD by 38% (OR 0.62, 95% CI 0.42–0.91; Model 1; Table 3). This association remained unaffected by additional adjustments for other known CVD-risk related factors, including current smoking (pack-years of smoking were also included in the model to incorporate lifelong smoking habit, without any alterations in the results), physical activity (defined as reporting physical activities on the IPAQ), and Mediterranean diet adherence (Model 2), as well as for hypertension, diabetes and hypercholesterolemia (Model 3). Further adjusting for IL-6 plasma levels did not substantively affect this relationship, which was modestly attenuated by additional adjustment for circulating CRP (Model 4 and Model 5, respectively; Table 3).

Discussion

Our study presents long-term, prospective data showing that circulating adiponectin holds a significant inverse association with the 10-year CVD incidence in adults from the Greek general population without previous CVD,

independently of several other established CVD risk factors. Indeed, in the context of the ATTICA study, this inverse association remained significant even after taking into account a range of factors related to CVD risk, including age, sex, BMI, waist circumference, smoking, physical activity, Mediterranean diet adherence, hypertension, diabetes, and hypercholesterolemia. As such, this multi-adjusted logistic regression analysis showed that in our study sample an increment of 1 unit in circulating total adiponectin levels was associated with 36% lower CVD risk. Moreover, this association persisted and was essentially unaffected even after further adjustment for IL-6 plasma levels, while it was modestly attenuated by the additional adjustment for circulating CRP. This suggests that the mechanisms linking adiponectin to lower long-term CVD risk in our study population extend beyond the underlying low-grade inflammation, as expressed by these two key pro-inflammatory biomarkers.

Our study findings agree with previous epidemiological data indicating a protective association between circulating adiponectin and development of CVD [11, 22–31]. Following the initial study by Pischon et al. in 2004 which showed that higher plasma adiponectin levels were independently associated with lower risk of subsequent CHD in middle-aged CVD-free men, a number of subsequent studies have documented similar, at least to some extent, findings in various cohorts [22–29]. Furthermore, meta-analysis data from prospective studies with a follow-up period ranging from 4 to 20 years (eight nested case–control and four cohort studies; total of 14,960 participants and 4132 incident CHD events) have also showed that higher circulating total adiponectin levels were independently associated with lower CHD risk in men and women [30]. Similarly, a CVD-protective effect of adiponectin was also noted in a meta-analysis of 17 case–control studies in Han Chinese subjects, showing that low total adiponectin circulating levels increased the risk of a first CVD event in the Han Chinese population [31].

This inverse association between circulating adiponectin and CVD can be attributed to a spectrum of adiponectin-induced anti-inflammatory, anti-atherogenic, and cardiovascular-protective effects which can directly impact on endothelial function, atherosclerosis and cardiomyocytes [4–7, 32–34]. As such, anti-inflammatory adiponectin effects appear to play a key role against endothelial dysfunction and atherogenesis by inhibiting the pro-inflammatory cascade in endothelial cells [34–36]. Moreover, in these cells adiponectin can also suppress the excess production of reactive oxygen species induced by high-glucose conditions or oxidized-LDL, thus protecting the vasculature in T2DM [37]. Notably, adiponectin can further exert vasodilator actions by directly stimulating nitric oxide production in endothelial cells [38]. In addition, adiponectin

may protect against the activation of the endothelial adhesion molecular cascade which facilitates the entry of macrophages into the vascular wall [39], and also suppress the macrophage to foam cell transformation process [40]. Finally, adiponectin has been shown to exert direct cardio-protective effects against ischemic myocardial injury, heart failure, and cardiac hypertrophy [4, 32–34, 41–43]. Indeed, adiponectin can protect against myocardial ischemia/reperfusion injury through signaling pathways involving both anti-inflammatory and anti-apoptotic actions [42, 43]. Interestingly, based on animal studies exploring cardiac remodeling after myocardial infarction, adiponectin may protect against systolic dysfunction following myocardial infarction by suppressing interstitial fibrosis and cardiac hypertrophy [44].

Despite the aforementioned prospective studies and the mounting experimental evidence supporting a direct protective role of circulating adiponectin in CVD, we must highlight that there is also a significant body of epidemiological data from studies that have found either a weaker than expected association between adiponectin plasma levels and CVD or no association at all [12, 45–55]. Furthermore, there are also meta-analyses of prospective studies reporting lack of a direct association between circulating adiponectin and CHD or stroke [12, 55–57]. This inconsistency and the conflicting findings in the literature can be attributed, at least in part, to differences between these studies in the design, studied population, follow-up duration and methodology (e.g., storing of samples and assays for adiponectin measurement), as well as to the various degrees of adjustment for confounding factors. For example, smoking is shown to influence the links between pro-inflammatory processes, metabolic syndrome and CVD [58], as well as circulating adiponectin levels [59–61], thus adjustments for smoking habits are required when exploring these associations. However, it appears that additional factors implicated in the complex role of adiponectin in health and disease states are also responsible for the conflicting epidemiological data (e.g., circulating adiponectin forms, expression/role of adiponectin receptors, and regulation of adiponectin secretion/actions).

Of note, adiponectin undergoes post-translational modifications within adipocytes, resulting in multimerization [62, 63]. As such, adiponectin is secreted as oligomers of trimers which circulate as low molecular weight (LMW: trimers or alternatively both trimers and hexamers), medium molecular weight (MMW: hexamers), and high molecular weight multimers (HMW: 18- to 36-mers) [3, 62, 63]. The latter predominates in plasma and appears to be more metabolically active [62, 63]. Thus, in addition to differences regarding the assays used to measure adiponectin, measurement of different forms of circulating adiponectin

(total or HMW) in various studies may also contribute to the noted inconsistency in reported findings.

Moreover, emerging evidence indicates that the adiponectin receptors further influence the circulating levels and role of adiponectin, particularly in relation to CVD [10, 32, 64, 65]. Adiponectin acts by binding to AdipoR1 (expressed ubiquitously; highest expression in skeletal muscle), AdipoR2 (expressed predominantly in the liver), and T-cadherin (a glycosylphosphatidylinositol-anchored extracellular protein without an intracellular domain, highly expressed in the heart, skeletal muscle and in endothelial and vascular smooth muscle cells) [32, 64, 65]. Both AdipoR1 and AdipoR2 are seven-transmembrane receptors and are also expressed in endothelial and vascular smooth muscle cells, as well as in the heart where AdipoR1 has relatively greater expression than AdipoR2 [32, 64]. Notably, T-cadherin is markedly expressed in endothelial and smooth muscle cells at sites of vascular injury and exhibits affinity only for the hexameric and HMW adiponectin forms [65]. As such, these adiponectin forms interact with T-cadherin and are abundantly present on vascular and muscle tissue surfaces where T-cadherin is highly expressed, forming a local reservoir [32, 64, 66]. This interaction is considered significant for the cardio-protective adiponectin effects and for the role of this adipokine in atherosclerosis [10, 32, 64, 66]. However, the exact mechanism(s) linking these receptors to the effects of adiponectin in the context of CVD remain to be clarified.

Notably, factors relating to the regulation of adiponectin synthesis/secretion, the adiponectin forms, and the adiponectin receptors may also be implicated in gender-specific differences noted in the relationship between circulating adiponectin and cardiometabolic complications [11, 22–24, 46, 49, 67]. Indeed, men appear to exhibit lower adiponectin plasma levels, potentially due to suppression by androgens [68]. However, women may also have lower circulating adiponectin levels after adjusting for body composition [69]. The latter indicates that the higher adiponectin plasma levels in women can be attributed to a more favorable body composition profile with less visceral/central adiposity [69]. As such, sex and body composition parameters should be taken into account when exploring the association of circulating adiponectin with CVD. Of note, opposing gender-specific associations between circulating HMW adiponectin and circulating T-cadherin levels have been noted in patients with stable coronary artery disease [70]. Moreover, different genotypes of adiponectin could be associated with higher CVD risk in a gender-specific way, since data suggest that the C/C carriers of the rs266729 SNP of adiponectin may have increased CVD mortality risk compared to the C/G or G/G carriers in women, but not in men [71]. Overall, whether gender-specific associations of circulating adiponectin with cardiometabolic complications

involve effects of sex hormones and/or sex-linked genes is not fully clarified yet and requires further research.

Finally, the so-called “adiponectin paradox” may also partly explain the conflicting evidence on the relationship between circulating adiponectin and CVD [10]. This paradox is noted mainly in older individuals and/or in certain patient groups (e.g., in patients with pre-existing CHD, chronic heart failure, or kidney disease) [10]. Indeed, studies in such populations have shown a positive association between high adiponectin plasma levels and increased mortality [10, 13–15]. This may be attributed to different factors which are considered to play a role in the relationship of circulating adiponectin with CVD in healthy subjects and in certain disease states [10]. According to this hypothesis, in healthy young and middle-aged adults the inverse association between circulating adiponectin and CVD is driven by increased adiposity (particularly central adiposity) and its pathophysiologic consequences (e.g., obesity-related low-grade inflammation) [10]. On the other hand, factors relating to cachexia, involuntary weight loss, and sarcopenia are considered to contribute to increased secretion of adiponectin in older individuals and in certain chronic diseases [10]. These factors may partly account for the observed link between high adiponectin plasma levels and increased overall and CVD mortality in such populations [10]. In addition, other mechanisms which can also cause increased circulating adiponectin levels in these populations appear to include: ineffective compensatory up-regulation of adiponectin synthesis; decreased adiponectin signaling efficacy (biological resistance); decreased renal elimination of circulating adiponectin; altered expression of adiponectin receptors (e.g., of T-cadherin); and stimulated adiponectin secretion by certain CVD-related factors (e.g., by increased levels of natriuretic peptides) [10]. Moreover, adiponectin can be also produced by cardiomyocytes, myocytes, and endothelial cells, and this non-adipose-derived adiponectin may also play a role in CVD [3, 10]. It becomes evident that multiple factors, alone or in synergy, may significantly influence the association of circulating adiponectin with CVD and, hence, should be taken into account when interpreting the findings of studies in this field.

In this context, it is also noteworthy that “paradoxical hyperadiponectinemia” has also been found in certain obese individuals who are considered metabolically healthy (i.e., individuals with BMI over 30 kg/m² who are without obesity-related metabolic complications, such as T2DM, hypertension, and dyslipidemia) [72–77]. These metabolically healthy obese subjects may exhibit paradoxically high adiponectin plasma levels despite the presence of obesity which is often long-standing and even severe/morbid [72–77]. Indeed, Aguilar-Salinas et al. have shown that 20% of obese adults (age range 18–70 years) with BMI over 40 kg/

m² have total adiponectin plasma levels higher than the median level of subjects with normal BMI [77]. Moreover, this study showed that total adiponectin plasma levels which were paradoxically high over certain thresholds had a positive association with the metabolically healthy obese phenotype, even after controlling for age, waist circumference and fasting insulin levels [77]. Similar findings have been also reported in obese adolescent girls [75, 76]. To what extent, in which specific patient groups (e.g., in which ethnic or age groups) and via which underlying mechanisms (e.g., links between adiponectin and the role of peripheral adiposity) this paradoxical hyperadiponectinemia may have a protective role against obesity-related cardio-metabolic complications remains to be further elucidated [72–77].

Strengths and limitations

The present work has several strengths since the association between circulating adiponectin and CVD incidence was studied in the context of a prospective study with a long (10-year) follow-up period that focused specifically in adults from the general population without CVD history. Such epidemiological data are sparse from Mediterranean countries. Indeed, this is the first long-term, prospective study on CVD epidemiology in Greece, with a cohort which is representative of the urban Greek population (participants living in the greater Athens metropolitan area, i.e., an urban region, reflecting almost 70% of the total Greek population). Furthermore, our study protocol involved assessments of multiple factors from all aspects of CVD risk determinants, including socio-demographic, lifestyle, clinical, and biochemical variables.

Despite these strengths, it is also important to acknowledge certain study limitations. As such, the relatively smaller sub-group of the ATTICA study participants with measured baseline circulating adiponectin levels could be considered a limitation of the present work. However, this sub-sample was representative of the total study's cohort without significant differences in the distributions of key factors. The low incidence of CVD noted in this study could be another limitation of the present analysis, but this was mainly due to the ATTICA study sampling scheme (i.e., enrolling participants from all age groups, representative to the total Greek population and without prior CVD); but this could be also viewed as a relative advantage, since it may reflect more precisely the true effect size of the studied factors on development of CVD in the general population compared to other studies that enrolled mainly participants of older age and/or participants with pre-existing CVD. Finally, based on our study protocol, we measured total levels of circulating adiponectin without selectively measuring HMW adiponectin plasma levels.

Conclusion

Our study shows that elevated circulating total adiponectin levels are independently associated with lower 10-year CVD risk in adults without previous CVD. This association appears to be modestly attenuated by circulating CRP levels, but it was not mediated by IL-6 which is the main endocrine/circulating pro-inflammatory cytokine. Our present findings add to the body of existing evidence on the relationship between total adiponectin plasma levels and incident CVD, and offer new data for a population that has been under-represented in long-term cardiovascular epidemiology studies.

Acknowledgements The authors would like to thank the ATTICA study group of investigators: Yannis Skoumas, Natasa Katinioti, Labros Papadimitriou, Constantina Masoura, Spiros Vellas, Yannis Lentzas, Manolis Kambaxis, Konstantina Paliou, Vassiliki Metaxa, Agathi Ntzouvani, Dimitris Mpougatas, Nikolaos Skourlis, Christina Papanikolaou, Aikaterini Kalogeropoulou, Evangelia Pitaraki, Alexandros Laskaris, Mihail Hatzigeorgiou, Athanasios Grekas, and Eleni Kokkou for assistance in the initial physical examination and/or the follow-up evaluation; Efi Tsetsekou for her assistance in psychological evaluation and follow-up evaluation, as well as the laboratory team: Carmen Vassiliadou and George Dedousis (genetic analysis), Marina Toutouza-Giotsa, Constantina Tselika and Sia Pouloupoulou (biochemical analysis), and Maria Toutouza for the database management.

Funding The ATTICA study is supported by research grants from the Hellenic Cardiology Society (HCS2002) and the Hellenic Atherosclerosis Society (HAS2003). Demosthenes Panagiotakos and Ekavi Georgousopoulou have received grants by the Coca-Cola Company.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

1. S. Galic, J.S. Oakhill, G.R. Steinberg, Adipose tissue as an endocrine organ. *Mol. Cell. Endocrinol.* **316**(2), 129–139 (2010)
2. C.M. Rondinone, Adipocyte-derived hormones, cytokines, and mediators. *Endocrine* **29**(1), 81–90 (2006)
3. M. Fasshauer, M. Blüher, Adipokines in health and disease. *Trends Pharmacol. Sci.* **36**(7), 461–470 (2015)
4. I. Kyrou, H.S. Mattu, K. Chatha, H.S. Randeve, Chapter 7—fat hormones, adipokines. in *Endocrinology of the Heart in Health and Disease*, ed. by J.C. Schisler, C.H. Lang, M.S. Willis (Academic Press, London, UK, San Diego, CA, 2017), pp. 167–205

5. K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordinon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. *Endocrine* **37**(1), 11–32 (2010)
6. R.S. Ahima, Metabolic actions of adipocyte hormones: focus on adiponectin. *Obesity* **14**(Suppl 1), 9S–15S (2006)
7. A.T. Turer, P.E. Scherer, Adiponectin: mechanistic insights and clinical implications. *Diabetologia* **55**(9), 2319–2326 (2012)
8. O. Yousuf, B.D. Mohanty, S.S. Martin, P.H. Joshi, M.J. Blaha, K. Nasir, R.S. Blumenthal, M.J. Budoff, High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? *J. Am. Coll. Cardiol.* **62**(5), 397–408 (2013)
9. J.S. Yudkin, M. Kumari, S.E. Humphries, V. Mohamed-Ali, Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? *Atherosclerosis* **148**(2), 209–214 (2000)
10. J.R. Kizer, Adiponectin, cardiovascular disease, and mortality: parsing the dual prognostic implications of a complex adipokine. *Metabolism* **63**(9), 1079–1083 (2014)
11. T. Pischon, C.J. Girman, G.S. Hotamisligil, N. Rifai, F.B. Hu, E. B. Rimm, Plasma adiponectin levels and risk of myocardial infarction in men. *JAMA* **291**(14), 1730–1737 (2004)
12. N. Sattar, G. Wannamethee, N. Sarwar, J. Tchernova, L. Cherry, A.M. Wallace, J. Danesh, P.H. Whincup, Adiponectin and coronary heart disease: a prospective study and meta-analysis. *Circulation* **114**(7), 623–629 (2006)
13. J. Poehls, C.L. Wassel, T.B. Harris, P.J. Havel, M.M. Swarbrick, S.R. Cummings, A.B. Newman, S. Satterfield, A.M. Kanaya, Health ABC study. Association of adiponectin with mortality in older adults: the health, aging, and body composition study. *Diabetologia* **52**(4), 591–595 (2009)
14. E. Cavusoglu, C. Ruwende, V. Chopra, S. Yanamadala, C. Eng, L.T. Clark, D.J. Pinsky, J.D. Marmur, Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. *Eur. Heart J.* **27**(19), 2300–2309 (2006)
15. C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, P. Hildebrandt, Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. *Circulation* **112**(12), 1756–1762 (2005)
16. C. Pitsavos, D.B. Panagiotakos, C. Chrysohoou, C. Stefanadis, Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. *BMC Public Health* **20**(3), 32 (2003)
17. K. Katsouyanni, E.B. Rimm, C. Gnardellis, D. Trichopoulos, E. Polychronopoulos, A. Trichopoulos, Reproducibility and relative validity of an extensive semi-quantitative food frequency questionnaire using dietary records and biochemical markers among Greek schoolteachers. *Int. J. Epidemiol.* **26**(Suppl 1), S118–S127 (1997)
18. D.B. Panagiotakos, C. Pitsavos, C. Stefanadis, Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. *Nutr. Metab. Cardiovasc. Dis.* **16**(8), 559–568 (2006)
19. G. Papathanasiou, G. Georgoudis, M. Papatheou, P. Spyropoulos, D. Georgakopoulos, V. Kalfakakou, A. Evangelou, Reliability measures of the short International Physical Activity Questionnaire (IPAQ) in Greek young adults. *Hell. J. Cardiol.* **50**(4), 283–294 (2009)
20. K.G. Alberti, P. Zimmet, J. Shaw IDF Epidemiology Task Force Consensus Group The metabolic syndrome—a new worldwide definition. *Lancet* **366**(9491), 1059–1062 (2005)
21. D.B. Panagiotakos, E.N. Georgousopoulou, C. Pitsavos, C. Chrysohoou, V. Metaxa, G.A. Georgiopoulos, K. Kalogeropoulou, D. Tousoulis, C. Stefanadis ATTICA Study Group Ten-year (2002–2012) cardiovascular disease incidence and all-cause mortality, in urban Greek population: the ATTICA Study. *Int. J. Cardiol.* **180**, 178–184 (2015)
22. D. Rothenbacher, H. Brenner, W. März, W. Koenig Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. *Eur. Heart J.* **26**(16), 1640–1646 (2005)
23. T. Pischon, F.B. Hu, C.J. Girman, N. Rifai, J.E. Manson, K.M. Rexrode, E.B. Rimm, Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. *Atherosclerosis* **219**(1), 322–329 (2011)
24. J. Frystyk, C. Berne, L. Berglund, K. Jensevik, A. Flyvbjerg, B. Zethelius, Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. *J. Clin. Endocrinol. Metab.* **92**(2), 571–576 (2007)
25. D.Y. Ho, N.R. Cook, K.A. Britton, E. Kim, M.A. Creager, P.M. Ridker, A.D. Pradhan, High-molecular-weight and total adiponectin levels and incident symptomatic peripheral artery disease in women: a prospective investigation. *Circulation* **124**(21), 2303–2311 (2011)
26. I. Saito, K. Yamagishi, C.L. Chei, R. Cui, T. Ohira, A. Kitamura, M. Kiyama, H. Imano, T. Okada, T. Kato, S. Hitsumoto, Y. Ishikawa, T. Tanigawa, H. Iso, Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels. *Atherosclerosis* **229**(1), 222–227 (2013)
27. M.B. Schulze, I. Shai, E.B. Rimm, T. Li, N. Rifai, F.B. Hu, Adiponectin and future coronary heart disease events among men with type 2 diabetes. *Diabetes* **54**(2), 534–539 (2005)
28. M. Kumada, S. Kihara, S. Sumitsuji, T. Kawamoto, S. Matsumoto, N. Ouchi, Y. Arita, Y. Okamoto, I. Shimomura, H. Hiraoka, T. Nakamura, T. Funahashi, Y. Matsuzawa; Osaka CAD Study Group, Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. *Arterioscler. Thromb. Vasc. Biol.* **23**(1), 85–9 (2003)
29. M. Ai, S. Otokozawa, B.F. Asztalos, C.C. White, L.A. Cupples, K. Nakajima, S. Lamon-Fava, P.W. Wilson, Y. Matsuzawa, E.J. Schaefer, Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. *Atherosclerosis* **217**(2), 543–548 (2011)
30. H. Zhang, X. Mo, Y. Hao, J. Huang, X. Lu, J. Cao, D. Gu, Adiponectin levels and risk of coronary heart disease: a meta-analysis of prospective studies. *Am. J. Med. Sci.* **345**(6), 455–461 (2013)
31. B.C. Zhang, W.J. Liu, W.L. Che, Y.W. Xu, Serum total adiponectin level and risk of cardiovascular disease in Han Chinese populations: a meta-analysis of 17 case-control studies. *Clin. Endocrinol.* **77**(3), 370–378 (2012)
32. J.L. Parker-Duffen, K. Walsh, Cardiometabolic effects of adiponectin. *Best Pract. Res. Clin. Endocrinol. Metab.* **28**(1), 81–91 (2014)
33. C. Caselli, A. D'Amico, M. Cabiati, T. Prescimone, S. Del Ry, D. Giannessi, Back to the heart: the protective role of adiponectin. *Pharmacol. Res.* **82**, 9–20 (2014)
34. T.A. Hopkins, N. Ouchi, R. Shibata, K. Walsh, Adiponectin actions in the cardiovascular system. *Cardiovasc. Res.* **74**(1), 11–18 (2007)
35. N. Ouchi, S. Kihara, Y. Arita, Y. Okamoto, K. Maeda, H. Kuriyama, K. Hotta, M. Nishida, M. Takahashi, M. Muraguchi, Y. Ohmoto, T. Nakamura, S. Yamashita, T. Funahashi, Y. Matsuzawa, Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF- κ B signaling through a cAMP-dependent pathway. *Circulation* **102**(11), 1296–1301 (2000)
36. Y. Hattori, Y. Nakano, S. Hattori, A. Tomizawa, K. Inukai, K. Kasai, High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF- κ B activation in vascular endothelial cells. *FEBS Lett.* **582**(12), 1719–1724 (2008)
37. R. Ouedraogo, X. Wu, S.Q. Xu, L. Fuchsel, H. Motoshima, K. Mahadev, K. Hough, R. Scalia, B.J. Goldstein, Adiponectin suppression of high-glucose-induced reactive oxygen species in

- vascular endothelial cells: evidence for involvement of a cAMP signaling pathway. *Diabetes* **55**(6), 1840–1846 (2006)
38. H. Chen, M. Montagnani, T. Funahashi, I. Shimomura, M.J. Quon, Adiponectin stimulates production of nitric oxide in vascular endothelial cells. *J. Biol. Chem.* **278**(45), 45021–45026 (2003)
 39. R. Ouedraogo, Y. Gong, B. Berzins, X. Wu, K. Mahadev, K. Hough, L. Chan, B.J. Goldstein, R. Scalia, Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. *J. Clin. Invest.* **117**(6), 1718–1726 (2007)
 40. N. Ouchi, S. Kihara, Y. Arita, M. Nishida, A. Matsuyama, Y. Okamoto, M. Ishigami, H. Kuriyama, K. Kishida, H. Nishizawa, K. Hotta, M. Muraguchi, Y. Ohmoto, S. Yamashita, T. Funahashi, Y. Matsuzawa, Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. *Circulation* **103**(8), 1057–63 (2001)
 41. M. Karmazyn, D.M. Purdham, V. Rajapurohitam, A. Zeidan, Signaling mechanisms underlying the metabolic and other effects of adipokines on the heart. *Cardiovasc. Res.* **79**(2), 279–286 (2008)
 42. N. Ouchi, R. Shibata, K. Walsh, Cardioprotection by adiponectin. *Trends Cardiovasc. Med.* **16**(5), 141–146 (2006)
 43. R. Shibata, K. Sato, D.R. Pimentel, Y. Takemura, S. Kihara, K. Ohashi, T. Funahashi, N. Ouchi, K. Walsh, Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. *Nat. Med.* **11**(10), 1096–1103 (2005)
 44. R. Shibata, Y. Izumiya, K. Sato, K. Papanicolaou, S. Kihara, W.S. Colucci, F. Sam, N. Ouchi, K. Walsh, Adiponectin protects against the development of systolic dysfunction following myocardial infarction. *J. Mol. Cell. Cardiol.* **42**(6), 1065–1074 (2007)
 45. R.S. Lindsay, H.E. Resnick, J. Zhu, M.L. Tun, B.V. Howard, Y. Zhang, J. Yeh, L.G. Best, Adiponectin and coronary heart disease: the Strong Heart Study. *Arterioscler. Thromb. Vasc. Biol.* **25**(3), e15–e16 (2005)
 46. G.A. Laughlin, E. Barrett-Connor, S. May, C. Langenberg, Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. *Am. J. Epidemiol.* **165**(2), 164–174 (2007)
 47. M. Côté, A. Cartier, A.Q. Reuwer, B.J. Arsenaault, I. Lemieux, J.P. Després, N.J. Wareham, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-norfolk prospective population study). *Am. J. Cardiol.* **108**(3), 367–373 (2011)
 48. W. Koenig, N. Khuseynova, J. Baumert, C. Meisinger, H. Löwel, Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. *J. Am. Coll. Cardiol.* **48**(7), 1369–1377 (2006)
 49. D.A. Lawlor, G. Davey Smith, S. Ebrahim, C. Thompson, N. Sattar, Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. *J. Clin. Endocrinol. Metab.* **90**(10), 5677–5683 (2005)
 50. L.H. Kuller, G. Grandits, J.D. Cohen, J.D. Neaton, R. Prineas; Multiple Risk Factor Intervention Trial Research Group, Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. *Atherosclerosis* **195**(1), 122–128 (2007)
 51. M. Matsumoto, S. Ishikawa, E. Kajii, Association of adiponectin with cerebrovascular disease: a nested case-control study. *Stroke* **39**(2), 323–328 (2008)
 52. N. Sattar, P. Watt, L. Cherry, S. Ebrahim, G. Davey Smith, D.A. Lawlor, High molecular weight adiponectin is not associated with incident coronary heart disease in older women: a nested prospective case-control study. *J. Clin. Endocrinol. Metab.* **93**(5), 1846–1849 (2008)
 53. Y. Hatano, M. Matsumoto, S. Ishikawa, E. Kajii, Plasma adiponectin level and myocardial infarction: the JMS cohort study. *J. Epidemiol.* **19**(2), 49–55 (2009)
 54. A.D. Ogorodnikova, S. Wassertheil-Smoller, P. Mancuso, M.R. Sowers, S.N. Rajpathak, M.A. Allison, A.E. Baird, B. Rodriguez, R.P. Wildman, High-molecular-weight adiponectin and incident ischemic stroke in postmenopausal women: a Women's Health Initiative Study. *Stroke* **41**(7), 1376–1381 (2010)
 55. M. Arregui, B. Buijsse, A. Fritsche, R. di Giuseppe, M.B. Schulze, S. Westphal, B. Isermann, H. Boeing, C. Weikert, Adiponectin and risk of stroke: prospective study and meta-analysis. *Stroke* **45**(1), 10–7 (2014)
 56. E. Sook Lee, S.S. Park, E. Kim, Y. Sook Yoon, H.Y. Ahn, C.Y. Park, Y. Ho Yun, S. Woo Oh, Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. *Int. J. Epidemiol.* **42**(4), 1029–1039 (2013)
 57. D.A. Kanhai, M.E. Kranendonk, C.S. Uiterwaal, Y. van der Graaf, L.J. Kappelle, F.L. Visseren, Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. *Obes. Rev.* **14**(7), 555–567 (2013)
 58. H. Cena, M.L. Fonte, G. Turconi, Relationship between smoking and metabolic syndrome. *Nutr Rev.* **69**(12), 745–753 (2011)
 59. J.S. Tsai, F.R. Guo, S.C. Chen, B.H. Lue, T.Y. Chiu, C.Y. Chen, S.H. Hung, L.M. Chuang, C.Y. Chen, Smokers show reduced circulating adiponectin levels and adiponectin mRNA expression in peripheral blood mononuclear cells. *Atherosclerosis* **218**(1), 168–173 (2011)
 60. K. Kotani, A. Hazama, A. Hagimoto, K. Saika, M. Shigeta, K. Katanoda, M. Nakamura, Adiponectin and smoking status: a systematic review. *J. Atheroscler. Thromb.* **19**(9), 787–794 (2012)
 61. M. Kryfti, K. Dimakou, M. Toumbis, Z. Daniil, C. Hatzoglou, K. I. Gourgoulianis, Effects of smoking cessation on serum leptin and adiponectin levels. *Tob. Induc. Dis.* **13**, 30 (2015)
 62. F. Simpson, J.P. Whitehead, Adiponectin—it's all about the modifications. *Int. J. Biochem. Cell Biol.* **42**(6), 785–788 (2010)
 63. Y. Wang, K.S. Lam, M.H. Yau, A. Xu, Post-translational modifications of adiponectin: mechanisms and functional implications. *Biochem. J.* **409**(3), 623–633 (2008)
 64. T. Yamauchi, M. Iwabu, M. Okada-Iwabu, T. Kadowaki, Adiponectin receptors: a review of their structure, function and how they work. *Best Pract. Res. Clin. Endocrinol. Metab.* **28**(1), 15–23 (2014)
 65. C. Hug, J. Wang, N.S. Ahmad, J.S. Bogan, T.S. Tsao, H.F. Lodish, T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. *Proc. Natl Acad. Sci. USA* **101**(28), 10308–10313 (2004)
 66. M.S. Denzel, M.C. Scimia, P.M. Zumstein, K. Walsh, P. Ruiz-Lozano, B. Ranscht, T-cadherin is critical for adiponectin-mediated cardioprotection in mice. *J. Clin. Invest.* **120**(12), 4342–4352 (2010)
 67. C. Menzaghi, M. Xu, L. Salvemini, C. De Bonis, G. Palladino, T. Huang, M. Copetti, Y. Zheng, Y. Li, G. Fini, F.B. Hu, S. Bacci, L. Qi, V. Trischitta, Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism. *Cardiovasc. Diabetol.* **13**, 130 (2014)
 68. H. Nishizawa, I. Shimomura, K. Kishida, N. Maeda, H. Kuriyama, H. Nagaretani, M. Matsuda, H. Kondo, N. Furuyama, S. Kihara, T. Nakamura, Y. Tochino, T. Funahashi, Y. Matsuzawa, Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. *Diabetes* **51**(9), 2734–41 (2002)
 69. J. Lew, M. Sanghavi, C.R. Ayers, D.K. McGuire, T. Omland, D. Atzler, M.O. Gore, I. Neeland, J.D. Berry, A. Khera, A. Rohatgi,

- J.A. de Lemos, Sex-based differences in cardiometabolic biomarkers. *Circulation* **135**(6), 544–555 (2017)
70. A.W. Schoenenberger, D. Pfaff, B. Dasen, A. Frisantiene, P. Erne, T.J. Resink, M. Philippova, Gender-specific associations between circulating T-cadherin and high molecular weight-adiponectin in patients with stable coronary artery disease. *PLoS One* **10**(6), e0131140 (2015)
71. U. Alehagen, E. Vorkapic, L. Ljungberg, T. Länne, D. Wågsäter, Gender difference in adiponectin associated with cardiovascular mortality. *BMC Med. Genet.* **16**, 37 (2015)
72. A. Muñoz-Garach, I. Cornejo-Pareja, F.J. Tinahones, Does metabolically healthy obesity exist? *Nutrients*. **8**(6), E320; 1–10 (2016)
73. S. Ahl, M. Guenther, S. Zhao, R. James, J. Marks, A. Szabo, S. Kidambi, Adiponectin levels differentiate metabolically healthy vs unhealthy among obese and nonobese white individuals. *J. Clin. Endocrinol. Metab.* **100**(11), 4172–4180 (2015)
74. A.P. Doumatey, A.R. Bentley, J. Zhou, H. Huang, A. Adeyemo, C.N. Rotimi, Paradoxical hyperadiponectinemia is associated with the metabolically healthy obese (MHO) phenotype in African Americans. *J. Endocrinol. Metab.* **2**(2), 51–65 (2012)
75. J.A. Morrison, C.J. Glueck, S. Daniels, P. Wang, D. Stroop, Paradoxically high adiponectin in obese 16-year-old girls protects against appearance of the metabolic syndrome and its components seven years later. *J. Pediatr.* **158**(2), 208–214.e1 (2011)
76. J.A. Morrison, C.J. Glueck, S. Daniels, P. Wang, P. Horn, D. Stroop, Paradoxically high adiponectin and the healthy obese phenotype in obese black and white 16-year-old girls. *Transl. Res.* **156**(5), 302–308 (2010)
77. C.A. Aguilar-Salinas, E.G. García, L. Robles, D. Riaño, D.G. Ruiz-Gomez, A.C. García-Ulloa, M.A. Melgarejo, M. Zamora, L. E. Guillen-Pineda, R. Mehta, S. Canizales-Quinteros, M.T. Tusie Luna, F.J. Gómez-Pérez, High adiponectin concentrations are associated with the metabolically healthy obese phenotype. *J. Clin. Endocrinol. Metab.* **93**(10), 4075–4079 (2008)